Long-term follow up data from investigator-initiated Phase II study with imlifidase (IdeS) to be presented at 2018 American Transplant Congress (ATC)
Hansa Medical AB (Nasdaq Stockholm: HMED), a biopharmaceutical company developing novel immunomodulatory enzymes, today announced that long-term follow up results from the ongoing investigator-initiated US study with imlifidase (IdeS) in highly sensitized patients will be presented in an oral session at the 2018 American Transplant Congress (ATC) in Seattle, U.S. on June 5.The long-term follow up results from the study, demonstrate that patients desensitized with imlifidase (IdeS) and transplanted with HLA-incompatible kidney show good renal function and minimal evidence of antibody